ATR and Patent ductus arteriosus: Mak et al. demonstrated that inhibiting more than one of the components of the ATR-CHK1-WEE1 pathway can overcome the pharmacological limitation of these inhibitors52, therefore supporting a potentially efficacious strategy to combine MK-1775 and CHK1 inhibitor in DDR-deficient PDA cells.